SCHEDULE: Oramed Increases Nano Dimension Stake, Opposes Deal

Oramed Pharmaceuticals has increased its stake in Nano Dimension to 7.2% and publicly declared opposition to the company's proposed transaction with Infinite Epigenetics.

Summary

• Oramed Pharmaceuticals Inc. increased its beneficial ownership in Nano Dimension Ltd. to 15,079,708 shares, representing a 7.2% stake.
• The reporting person expended approximately $8.7 million in open market purchases between May 13, 2026, and June 15, 2026.
• Oramed utilized significant derivative strategies, including the purchase and sale of various call and put options to manage its position.
• The filing explicitly states Oramed's strong opposition to Nano Dimension's proposed transaction with Infinite Epigenetics, citing it as not in the best interests of shareholders.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a negative development for management stability, as it highlights a public rift between the company and a significant shareholder regarding strategic direction.

Positives

• Increased institutional ownership by Oramed Pharmaceuticals signals confidence in the underlying value of Nano Dimension.
• The reporting person has demonstrated significant capital commitment, investing over $10 million in total across share purchases and derivative positions.

Negatives

• Public declaration of opposition to management's strategic direction creates corporate governance friction.
• The proposed transaction with Infinite Epigenetics is being actively challenged by a major shareholder.

Risks

• Potential for a proxy contest or further escalation of conflict between Oramed and Nano Dimension management.
• Market volatility resulting from the public disagreement over the proposed Infinite Epigenetics transaction.
• Uncertainty regarding the future strategic direction of Nano Dimension given the shareholder opposition.

Future Outlook

Oramed Pharmaceuticals is currently evaluating all available options regarding the proposed transaction with Infinite Epigenetics and remains strongly opposed to the deal.

Management Comments

• The Reporting Person believes the Proposed Transaction is not in the best interests of the Issuer's shareholders and is strongly opposed to it.

Industry Context

StockSavvy.ai notes that this filing represents a classic activist investor intervention, where a significant shareholder challenges a company's pivot into a new, potentially unrelated sector (AI-powered diagnostics) to protect shareholder value.

Comparison to Industry Standards

• The use of derivative instruments (puts/calls) to build a position is a sophisticated strategy common among activist hedge funds and institutional investors.
• Public opposition to M&A activity via Schedule 13D is a standard mechanism for institutional investors to signal dissent to the board of directors.

Stakeholder Impact

• Shareholders face uncertainty regarding the potential Infinite Epigenetics deal.
• Management faces increased pressure to justify the strategic pivot.

Next Steps

• Oramed to continue evaluating options regarding the proposed Infinite Epigenetics transaction.
• Potential for further regulatory filings or public statements from either party regarding the proposed deal.

Key Dates

Recommendation

The stock is currently in a state of strategic uncertainty due to activist opposition. Investors should hold until the outcome of the proposed transaction becomes clearer or until management provides a more compelling justification for the deal.

Keywords

Nano Dimension, Oramed Pharmaceuticals, Schedule 13D, Shareholder Activism, Corporate Governance, Infinite Epigenetics, Mergers and Acquisitions